Business Bites: J&J joins EU renal denervation fray; FDA recommends Inspire sleep apnea device
This article was originally published in Clinica
Executive Summary
Johnson & Johnson, through its Cordis division, has become the latest player in the European renal denervation sector, CE marking its Renlane device for drug-resistant hypertension. The firm joins Medtronic, St Jude Medical, Boston Scientific and Covidien, which already market renal denervation systems in Europe.